Cardiovascular outcomes trials with statins in diabetes

FARIHA NAEEM, GERARD MCKAY, MILES FISHER

Abstract
Treatment with statins is one of the most effective ways of reducing cardiovascular events in those with diabetes. Many studies containing thousands of subjects with diabetes have demonstrated that statins reduce cardiovascular events when there is no known cardiovascular disease (primary prevention) and in those with confirmed atherosclerotic disease (secondary prevention). High-dose statins appear to be even more effective in established cardiovascular disease, but at the expense of increased drug side effects. In this paper we review the evidence for the benefits of statins in diabetes. In a second review we will examine the evidence for possible benefits of other lipid-lowering therapies when these are added to background statin therapy in diabetes.

Br J Diabetes 2018;18:7-13

Key words: diabetes, hypercholesterolaemia, lipids, statins, cardiovascular disease

Introduction
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in those with diabetes mellitus. Diabetes is an independent risk factor for the development of CVD and the presence of diabetes is a poor prognostic marker in those with CVD. The increasing prevalence of diabetes worldwide and the burden on global healthcare that this represents makes developing strategies to improve cardiovascular outcomes a public health priority.

Most research on improving cardiovascular outcomes by addressing cardiovascular risk factors in diabetes relates to those with type 2 diabetes mellitus (T2DM), characterised by insulin resistance with variable degrees of beta-cell dysfunction, and is typically associated with abnormal lipid profiles, obesity and other features of the metabolic syndrome. In T2DM the abnormal lipid pattern consists of raised concentrations of triglycerides and low high-density lipoprotein cholesterol (HDL cholesterol) concentrations. Total levels of low density lipoprotein cholesterol (LDL cholesterol) are similar to populations without diabetes, but with a greater proportion of small-dense particles which are more atherogenic. By contrast, in type 1 diabetes mellitus (T1DM) that is well controlled, triglyceride levels tend to be lower and HDL cholesterol concentrations are average or even high.

Observational studies have demonstrated a strong positive relationship between raised LDL cholesterol levels and increasing risk of cardiovascular events. Lowering LDL cholesterol is thought to slow down the development and progression of atherosclerosis and decrease cardiovascular events. Statins have been in clinical use for 20 years and reduce LDL cholesterol by inhibiting 3-hydroxy-3-methylglutaryl (HMG CoA) reductase and decreasing endogenous production of LDL cholesterol in the liver.

This review revisits evidence from key randomised cardiovascular outcomes trials and meta-analyses on the cardiovascular benefits of statins in diabetes. In a future paper we will examine the results of newer studies with other lipid-lowering therapies in people with diabetes, including recent results on the effects of PCSK9 inhibitors in these patients.

Primary prevention trials (Table 1)

Studies in subjects with diabetes
Two studies have examined statin use for the primary prevention of CVD exclusively in those with diabetes. The Collaborative Atorvastatin Diabetes Study (CARDS) involved 2,838 subjects aged 40–75 from centres around the UK and Ireland who were randomised to either 10 mg atorvastatin or placebo. Participants had T2DM with no history of CVD, but had at least one other cardiovascular risk factor. The study was terminated 2 years early because the pre-specified stopping rule for efficacy in reducing cardiovascular events had been achieved. Subjects allocated to atorvastatin had a 37% significant reduction in the primary endpoint of acute coronary heart disease (CHD) events (myocardial infarction, unstable angina, acute CHD death, resuscitated cardiac arrest), coronary revascularisation or stroke. All-cause mortality was numerically lower in the atorvastatin group but was not statistically significantly reduced.

The Atorvastatin Study for Prevention of CHD Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN) study included 2,410 subjects with T2DM who were also assigned to receive 10 mg atorvastatin or placebo. This international study was originally intended to look at secondary prevention with a follow-up of 4 years; however, due to changing guidelines impairing recruitment, the protocol was changed and a primary prevention cohort were also recruited. For the primary prevention cohort a significant 30% reduction in LDL cholesterol levels was observed, but no beneficial
effect was found on the primary outcome which was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, recanalisation, coronary artery bypass surgery, resuscitated cardiac arrest and hospitalisation for unstable angina. Similar results were found in the small secondary prevention cohort. There are multiple limitations of this flawed study including the change in the study design, the multiple endpoints, the low risk of events in the primary prevention cohort and the extensive use of non-study lipid-lowering therapy in both groups.

Trials including large numbers of subjects with diabetes
Several studies have investigated statin use for primary prevention with substantial subgroups of subjects with diabetes. The Heart Protection Study (HPS) recruited 20,536 patients with CHD, other occlusive vascular disease or diabetes, and included 5,963 with diabetes. Simvastatin 40 mg or placebo was given over the course of 5 years. 2,912 of the participants with diabetes had no prior vascular disease (49%) (primary prevention) and in this subgroup the rate of the defined endpoint for subcategories which was major vascular events (cardiovascular death, non-fatal myocardial infarction, stroke, revascularisation) was reduced significantly from 13% to 9% in the group receiving simvastatin.1

The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) looked at hypertensive treatment in subjects aged 55 years or older. Within this study the Lipid-Lowering trial component (ALLHAT-LLT) randomised 10,355 subjects, including 3,638 (35%) with T2DM, to open label pravastatin treatment or usual care. No significant difference was found in all-cause mortality (primary outcome) or CHD outcomes (secondary outcome of fatal CHD, non-fatal myocardial infarction) in the whole study group or in the subgroup with diabetes.9 One reason for these negative results may be the relatively high rates of statin use in the usual care group, reaching nearly 25%, as intensive lipid lowering became a routine part of clinical care following the presentation and publication of other statin studies.

The landmark Scandinavian Simvastatin Survival Study (4S) recruited 4,444 patients with a prior history of CHD and hypercholesterolaemia who were randomised to treatment with 20–40 mg simvastatin or placebo.13 Over a median duration of 5.4 years of follow-up, those randomised to simvastatin had a significant reduction in all-cause mortality and major CHD events, and this included

![Table 1 Diabetes results from key primary prevention studies](https://example.com/table1)

<table>
<thead>
<tr>
<th>Study (year of primary publication)</th>
<th>Comparison</th>
<th>Subjects</th>
<th>Subjects with diabetes (%)</th>
<th>Diabetes results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARDS (2004)</td>
<td>Atorvastatin 10 mg vs placebo</td>
<td>2,838</td>
<td>2,838 (100%)</td>
<td>Significant reduction in LDL cholesterol</td>
</tr>
<tr>
<td>ASPEN (2006)</td>
<td>Atorvastatin 10 mg vs placebo</td>
<td>2,410</td>
<td>2,410 (100%), 1,905 primary prevention</td>
<td>No significant reduction in primary prevention</td>
</tr>
<tr>
<td>HPS (2002)</td>
<td>Simvastatin 40 mg vs placebo</td>
<td>20,536</td>
<td>5,963 (28%), 2912 primary prevention</td>
<td>Significant reduction in defined endpoint for subcategories</td>
</tr>
<tr>
<td>ALLHAT-LLT (2002)</td>
<td>Pravastatin 40 mg vs usual care</td>
<td>10,355</td>
<td>3,638 (35%)</td>
<td>No significant reduction in primary prevention</td>
</tr>
<tr>
<td>ASCOT-LLA (2003)</td>
<td>Atorvastatin 10 mg vs placebo</td>
<td>10,305</td>
<td>2,532 (25%)</td>
<td>Significant reduction in major cardiovascular events or procedures</td>
</tr>
<tr>
<td>MEGA (2006)</td>
<td>Pravastatin 10–20 mg vs usual care</td>
<td>7,832</td>
<td>1,632 (21%)</td>
<td>Significant reduction in coronary heart disease events</td>
</tr>
</tbody>
</table>
a significant reduction in CHD events in the small subgroup of 202 with diabetes. A later post-hoc analysis was performed using newer diagnostic criteria for T2DM and confirmed a significant reduction in CHD events in 483 subjects with baseline diabetes.

The Cholesterol and Recurrent Events (CARE) trial was a secondary prevention study comparing pravastatin 40 mg with placebo in 4,159 patients with a history of CHD and average cholesterol levels. The incidence of the primary endpoint of a fatal coronary event or non-fatal myocardial infarction was significantly reduced by 24% in the treatment group overall, demonstrating benefit of statin use in secondary prevention even in the absence of raised LDL cholesterol levels. In the 586 subjects with diabetes (14%), the reduction in the primary endpoint was not significant but there was a 25% significant reduction in an expanded coronary endpoint.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial involved a larger cohort of 9,014 patients with CHD, with 1,077 (12%) diagnosed as having diabetes at baseline. Overall, pravastatin 40 mg significantly reduced the primary outcome of mortality from CHD, and in a pre-specified subgroup analysis, pravastatin reduced the occurrence of major CHD events and major coronary events (CHD death or non-fatal myocardial infarction) in the subgroup with diabetes.

In the Heart Protection Study (HPS) 3,051 of the 5,963 subjects with diabetes (51%) had prior CHD or other occlusive vascular disease. Simvastatin 40 mg significantly reduced the rate of major vascular events in those with diabetes and prior CHD (from 38% to 33%) or other CVD (from 33% to 26%).

A detailed description of evidence for the reduction of cardiovascular events with statins in the setting of diabetes and chronic kidney disease is beyond the scope of this review. A guideline for the management of lipids in adults with diabetes and/or chronic kidney disease was recently published in the British Journal of Diabetes and contains the evidence base for this treatment.

The 4D study is worthy of mention, however, as it included only patients with T2DM on maintenance haemodialysis. Most of the patients in the 4D study had some form of vascular disease at baseline. No benefit on major adverse cardiovascular events (MACE) (cardiovascular death, myocardial infarction, stroke) was found comparing atorvastatin 20 mg to placebo over the 4 years of the study. The authors postulated that initiating lipid-lowering therapy in this group of patients might be too late to observe beneficial effects. They also suggested that the pathogenesis of vascular events might be different in people with T2DM and nephropathy compared to people with T2DM and no renal complications. Additional factors in patients with renal failure such as sympathetic overactivity, left ventricular hypertrophy and cardiac fibrosis may contribute to CVD rather than the more traditional factors leading to atherosclerotic disease. A recent post-hoc analysis followed subjects up for a median of 11.5 years, and although MACE was not reduced, the risk of all cardiac events combined and the risk of cardiovascular death was significantly lower in the original atorvastatin group compared with the placebo group.

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial studied atorvastatin 80 mg or placebo in 4,731 patients with recent stroke or transient ischaemic attack but no known coronary disease. Overall there was a significant reduction in further fatal or non-fatal strokes with atorvastatin. Subgroup analysis of 794 subjects (17%) classified as having diabetes at baseline showed atorvastatin therapy did not significantly reduce the risk of further stroke, but did significantly reduce the risk of major coronary events, major cardiovascular events (MACE), any CHD event and revascularisation procedures.

Thus, most studies have demonstrated significant benefits of statin therapy for secondary prevention of CVD in people with diabetes (Table 2). Guidelines reflect this by recommending statin

### Table 2 Diabetes results from key secondary prevention studies

<table>
<thead>
<tr>
<th>Study (year of primary publication)</th>
<th>Comparison</th>
<th>Subjects</th>
<th>Subjects with diabetes (%)</th>
<th>Diabetes results</th>
</tr>
</thead>
<tbody>
<tr>
<td>4S (1994)</td>
<td>Simvastatin 20–40 mg vs placebo</td>
<td>4,444</td>
<td>202 (5%)</td>
<td>No significant reduction in total mortality, significant 55% reduction in major coronary events</td>
</tr>
<tr>
<td>CARE (1996)</td>
<td>Pravastatin 40 mg vs placebo</td>
<td>4,159</td>
<td>586 (14%)</td>
<td>No significant reduction in major coronary events, significant 25% reduction in expanded coronary event</td>
</tr>
<tr>
<td>LIPID (1998)</td>
<td>Pravastatin 40 mg vs placebo</td>
<td>9,014</td>
<td>1,077 (12%)</td>
<td>No significant reduction in major coronary events, significant 21% reduction in any cardiovascular event</td>
</tr>
<tr>
<td>HPS (2002)</td>
<td>Simvastatin 40 mg vs usual care</td>
<td>20,536</td>
<td>5,963 (28%), 3,051 secondary prevention</td>
<td>Significant reduction in defined endpoint for subcategories</td>
</tr>
<tr>
<td>4D (2005)</td>
<td>Atorvastatin 20 mg vs placebo</td>
<td>1,255</td>
<td>1,255 (100%)</td>
<td>No significant reduction in MACE</td>
</tr>
<tr>
<td>SPARCL (2006)</td>
<td>Atorvastatin 80 mg vs placebo</td>
<td>4,731</td>
<td>794 (17%)</td>
<td>No significant reduction in strokes, significant reduction in major coronary events and MACE</td>
</tr>
</tbody>
</table>
therapy in the presence of prior atherosclerotic CVD, regardless of baseline LDL cholesterol concentrations or other cardiovascular risk factors.

**Evidence for benefits of high-dose versus low-dose statins in diabetes (Table 3)**

Observational studies have shown a continuous positive relationship between LDL cholesterol concentrations and CVD. It follows that a greater reduction in LDL cholesterol might reduce the cardiovascular risk even further. A small number of studies, with mixed results, have compared high-dose versus low-dose statins to establish whether intensive lipid lowering improves cardiovascular outcomes, including substantial numbers of subjects with diabetes.

The Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) Thrombolysis in Myocardial Infarction (TIMI) 22 trial compared standard-dose pravastatin versus high-dose atorvastatin in people with recent acute coronary syndromes. High intensity statin treatment significantly reduced the primary extended cardiovascular composite end point by 16% in the general study population. Nearly one quarter of the subjects in PROVE IT had diabetes and, although subgroup analysis showed a reduction in primary end points in the high intensity group, this did not reach statistical significance. The authors attributed this to the substudy being underpowered. A secondary ‘triple’ endpoint of acute cardiac events (death, myocardial infarction, unstable angina) was significantly reduced. A higher number of people in the intensive arm had abnormal liver function tests, but the rates of discontinuation of statin therapy due to side effects was not significantly different between groups.

The Treating to New Targets (TNT) study compared high-dose versus low-dose atorvastatin in 10,001 people with stable CHD. 1,501 (15%) of the subjects had diabetes and subgroup analysis showed high-dose atorvastatin appeared to be beneficial in significantly reducing the risk of major cardiovascular events (CHD death, myocardial infarction, stroke, resuscitation after cardiac arrest) by 25%. Safety analysis demonstrated a significantly greater number of adverse events in the intensively treated group, particularly an increase in abnormal liver function tests, with no significant differences between the rates of reported myalgia and rhabdomyolysis in both groups.

Three other studies comparing high-dose and low-dose statin therapy gave disappointing results. The A to Z trial compared simvastatin 40 mg then 80 mg with placebo then simvastatin 20 mg in 4,497 subjects following an acute coronary syndrome. 1,059 subjects had diabetes at baseline (24%). There was a nonsignificant trend towards overall benefit in reducing the primary endpoint and also in subjects with diabetes, but this was not significant and the number of events was less than anticipated. The Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study compared atorvastain 80 mg with simvastatin 20 mg in 8,888 subjects with a previous history of myocardial infarction, including 1,069 subjects with diabetes (12%). The primary endpoint of major coronary events was not significantly reduced, but when the same endpoints as TNT or PROVE IT were examined, statistically significant reductions were observed. The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial was even more disappointing, and an insignificant 6% reduction in major vascular events was observed comparing simvastatin 80 mg with simvastatin 20 mg in 12,064 survivors of myocardial infarction, 1,267 of whom (11%) had diabetes at baseline.

In summary, high intensity statin treatment, especially atorvastatin 80 mg, appeared to have some potential benefit in preventing further CVD in those with diabetes and atherosclerotic CVD. Intensive therapy was associated with greater side effects, particularly abnormal liver function tests.

**Table 3** Diabetes results from studies comparing low-dose and high-dose statins

<table>
<thead>
<tr>
<th>Study (year of primary publication)</th>
<th>Comparison</th>
<th>Subjects</th>
<th>Subjects with diabetes (%)</th>
<th>Diabetes results</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROVE IT (2004)</td>
<td>Atorvastatin 80 mg vs pravastatin 40 mg</td>
<td>4,162</td>
<td>978 (23%)</td>
<td>Significant 25% reduction in acute cardiac events</td>
</tr>
<tr>
<td>A to Z (2004)</td>
<td>Simvastatin 40 mg then 80 mg vs placebo then simvastatin 20 mg</td>
<td>4,497</td>
<td>1,059 (24%)</td>
<td>Insignificant reduction in primary endpoint</td>
</tr>
<tr>
<td>TNT (2005)</td>
<td>Atorvastatin 80 mg vs atorvastatin 10 mg</td>
<td>10,001</td>
<td>1,501 (15%)</td>
<td>Significant 25% reduction in major cardiovascular events</td>
</tr>
<tr>
<td>IDEAL (2005)</td>
<td>Atorvastatin 80 mg vs simvastatin 20–40 mg</td>
<td>8,888</td>
<td>1,069 (12%)</td>
<td>Overall no significant reduction in primary endpoint, diabetes subgroup not reported</td>
</tr>
<tr>
<td>SEARCH (2010)</td>
<td>Simvastatin 80 mg vs simvastatin 20 mg</td>
<td>12,064</td>
<td>1,267 (11%)</td>
<td>Overall no significant reduction in primary endpoint, diabetes subgroup not reported</td>
</tr>
</tbody>
</table>

**Meta-analysis of randomised controlled trials in people with diabetes**

There have been several meta-analyses of diabetes data from cardiovascular outcome trials of statins. By far the most important of these is the Cholesterol Treatment Trialsists’ (CTT) collaboration which used individual patient data rather than summary data. This
collaboration was established before the results of any of these studies were available, and the first meta-analysis included individual patient data from 90,056 subjects in 14 randomised controlled trials of statin therapy. Studies that contributed to the meta-analysis comprised ALLHAT-LLT, ASCOT-LLA, CARDS, CARE, HPS, LIPID and 45 trials, which are described above, plus three other studies of primary prevention (AFCAPS/TexCAPS, PROSPER, WOSCOPS), three secondary prevention studies (GISSI-P, LIPS, Post-CABG) and one study in subjects post renal transplantation (ALERT). 18,686 of the participants had diabetes, including 1,466 subjects with T1DM (2% of the total) and 17,220 with T2DM (19% of the total). The results were strongly positive with a 9% reduction in all-cause mortality for every 1 mmol reduction in LDL cholesterol with statins. This was irrespective of whether vascular disease was present prior to study recruitment (secondary prevention) or there was no known vascular disease (primary prevention). The proportional effect was similar in patients with T1DM and T2DM.

Back to back with the publication of the SEARCH trial, the Cholesterol Treatment Trialists’ Collaboration produced a further meta-analysis of trials with at least 1,000 participants each with a follow-up duration of 2 years. They identified the five trials described earlier (A to Z, IDEAL, PROVE IT, SEARCH, TNT) and 21 trials of statins versus control. The results of intensive statin treatment were overwhelmingly positive and showed that more intensive lipid lowering led to a 15% further reduction in major vascular events compared with standard lipid lowering. Between 11% and 24% of people had diabetes in these five trials and the significant impact upon cardiovascular events was seen in both T1DM and T2DM. In terms of side effects of intensive therapy, only cases of rhabdomyolysis were investigated and these appeared to be related to the use of simvastatin 80 mg daily.

Three other meta-analyses have been published, but these do not add new findings to the CTTC analyses. The first looked at data from seven randomised controlled trials of primary prevention (AFCAPS/TexCAPS, ASPEN, ASCOT-LLA, CARDS, HPS, MEGA, PROSPER) including 12,711 patients with diabetes. Statin therapy was associated with a significant 21% reduction in the incidence of cardiovascular events. No significant difference was found in all-cause mortality between statin-treated and control groups although all-cause mortality was only reported in three studies so this may have been underpowered for this outcome.

A further meta-analysis of 22 trials was conducted and found that statin therapy significantly reduced by 21% the incidence of CVD in subjects with diabetes. Finally, a recent meta-analysis included five studies of statin versus placebo (ASPIN, CARE, LIPID, HPS, 4S) and four studies of high-dose versus low-dose statins (A to Z, PROVE IT, SEARCH, TNT) and concluded that, compared with placebo, statin treatment reduced major cardiovascular or cerebrovascular events by 15% in subjects with diabetes, with a further 9% reduction comparing high-dose with low-dose statins.

Conclusion

Statin therapy is generally well tolerated and the risk of myopathy, myositis and rhabdomyolysis associated with statin use is rare. Statin therapy slightly increases the development of new diabetes, and this is more marked with higher dose statins. The metabolic side effects of statins in people with diabetes are a minor increase in HbA1C of 1.3 mmol/mol (0.12%), but this is trivial compared with the overwhelming evidence of cardiovascular risk reduction. For primary prevention, most trials and meta-analyses have demonstrated a significant benefit of statin therapy in reducing cardiovascular events in those with diabetes. For secondary prevention, intensive lipid-lowering regimens with high-dose statins have an even greater benefit compared with standard lipid-lowering treatments in further reducing cardiovascular events, but higher doses may not be tolerated due to an increase in side effects.

Conflict of interest

FN none declared. GMcK has received payment for advisory boards and/or lectures from MSD and Pfizer. MF has received payment for advisory boards and/or lectures from AstraZeneca, MSD and Pfizer.

Funding

None.

References

8. ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin...


